1 University of Cambridge, Department of Haematology, CIMR Centre, Hills Road, Cambridge CB2 2XY, UK
2 Johannes Gutenberg-University, Institute of Toxicology, Laboratory of Molecular Mouse Genetics, Obere Zahlbacher Str. 67, 55131 Mainz, Germany
*Author for correspondence (e-mail: mss24{at}cus.cam.ac.uk)
Accepted September 10, 2001
![]() |
SUMMARY |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Key words: Scl gene, Stem cell enhancer, Haematopoietic Stem cells, Mouse
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
During mouse embryogenesis, the first morphological evidence of haematopoietic activity occurs at day 7.5 of gestation (E7.5) in the yolk sac blood islands derived from the extra-embryonic mesoderm. By E8, the yolk sac contains haemoglobin producing erythroid cells together with multipotent erythroid/myeloid progenitors (Cumano et al., 1996; Palis et al., 1999). Around the same developmental time and preceding the onset of blood circulation, the intra-embryonic para-aortic splanchnopleura region contains multipotent lymphoid/erythroid/myeloid progenitors (Cumano et al., 1996). These results suggest that haematopoietic cells in the mouse arise independently in the yolk sac and para-aortic splanchnopleura, a model analogous to the situation in birds (Dieterlen-Lievre, 1975).
It has been assumed that HSCs are also present at early stages of development, but no functional demonstration is available before E9. Thus, HSC activity is first detected in yolk sac and para-aortic splanchnopleura around E9, within the c-Kit+CD34+ population (Weissman et al., 1978; Yoder et al., 1997). These cells are capable of long-term reconstitution if transplanted into foetal or new born recipients but do not engraft adult recipients, suggesting that they lack a homing activity for adult bone marrow. c-Kit+CD34+ HSCs capable of long-term reconstitution in adult recipient mice are detected from day 10 of gestation in the aorta, gonads and mesonephros (AGM) region, a derivative of the para-aortic splanchnopleura region (de Bruijn et al., 2000; Medvinsky and Dzierzak, 1996; Muller et al., 1994; Sanchez et al., 1996) and are found subsequently in the foetal liver and adult bone marrow (Jordan et al., 1990; Morrison et al., 1995; Spangrude et al., 1988). The lineage relationship between multipotent progenitors/HSCs arising in the murine yolk sac and AGM remains unclear in the mouse. However lineage tracing studies in Xenopus have recently shown that the yolk sac (ventral blood islands) and intraembryonic (dorsolateral plate) blood components derive from distinct blastomeres in 32-cell embryos, strongly suggesting that the first adult HSCs arise independently of yolk sac haematopoiesis (Ciau-Uitz et al., 2000)
Although the mechanisms that control HSC differentiation and self-renewal are largely unknown, loss-of-function and gain-of-function studies have demonstrated a pivotal role for transcription factors. Yolk sac, foetal liver or adult haematopoiesis can be differentially affected by the loss of a particular transcription factor indicating intrinsic differences in the transcriptional regulation of haematopoiesis in different sites (Mucenski et al., 1991; Tsai et al., 1994; Wang et al., 1998; Wang et al., 1996). Among the regulatory molecules crucial for the proper development of embryonic and adult haematopoiesis is the bHLH transcription factor encoded by the stem cell leukaemia gene, Scl (Tal1 Mouse Genome Informatics) (Begley and Green, 1999). Scl is expressed in blood cells, endothelium and the central nervous system (Drake et al., 1997; Drake and Fleming, 2000; Green et al., 1991; Green et al., 1992; Hwang et al., 1993; Kallianpur et al., 1994; Silver and Palis, 1997; Sinclair et al., 1999; Visvader et al., 1991). Within the haematopoietic cells, SCL is found in multipotent progenitors, as well as in the erythroid, megakaryocytic and mast cell lineages (Cross et al., 1994; Green et al., 1992; Visvader et al., 1991), and is expressed at all sites of haematopoiesis in the mouse embryo, including the yolk sac, paraortic splanchnopleura, AGM region and foetal liver (Elefanty et al., 1999; Silver and Palis, 1997).
SCL is essential for normal yolk sac and adult haematopoiesis (Porcher et al., 1996; Robb et al., 1996; Robb et al., 1995; Shivdasani et al., 1995). It also plays an important role in endothelial development. Scl/ embryos exhibit defective yolk sac angiogenesis, which appears to reflect an intrinsic defect in Scl/ endothelial cells (Visvader et al., 1998). In addition, two lines of evidence suggest a crucial role for SCL in the development of haemangioblasts, common progenitors of both blood and endothelium. First, ectopic expression of Scl during zebrafish development specifies haemangioblast formation from lateral mesoderm at the expense of other mesodermal derivatives (Gering et al., 1998), and can also partially rescue the blood and endothelial defects of cloche mutants (Liao et al., 1998). Second, Scl/ ES cells fail to differentiate in vitro to form blast cell colonies that are thought to arise from haemangioblasts (Faloon et al., 2000; Robertson et al., 2000).
There is considerable interest in identifying a regulatory element that targets expression to HSCs. Characterisation of such an enhancer would generate important insights into the transcriptional programmes responsible for haematopoiesis, and would also provide a powerful tool for experimental manipulation of these processes in vivo. Regulatory elements from the Ly-6E.1 gene (Ly6a Mouse Genome Informatics) (Miles et al., 1997) and the H2K gene (Domen et al., 2000) have been used to target adult HSCs. However, the expression of Ly6E.1 in HSC is mouse strain dependent (Codias et al., 1989; Spangrude et al., 1988), and the H2K gene is widely expressed in most tissues. Moreover an expression cassette capable of targeting adult, foetal and embryonic HSCs has not been described.
We have therefore performed a systematic survey of the promoters and chromatin structure of the murine Scl gene and identified several regulatory elements active in transient and stable transfection assays (Bockamp et al., 1998; Bockamp et al., 1997; Bockamp et al., 1995; Gottgens et al., 1997). Analysis of reporter constructs in transgenic mice subsequently revealed a panel of spatially distinct enhancers, each of which directs expression to a subdomain of the normal Scl expression pattern (Gottgens et al., 2000; Sanchez et al., 1999; Sinclair et al., 1999). A 3' enhancer reporter construct was active in haematopoietic progenitors and vascular endothelium during development (Sanchez et al., 1999) but did not direct expression to most mature haematopoietic cells, including erythroid cells. We demonstrate that an Scl 3' enhancer construct directs expression to long term repopulating HSCs in foetal liver and adult bone marrow. Furthermore, in Scl/ embryos expression of exogenous Scl under control of the 3' enhancer selectively rescued the formation of early haematopoietic progenitors and yolk sac angiogenesis, but failed to rescue significant levels of erythropoiesis, thus revealing a requirement for SCL during erythroid differentiation.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Transgenic mice carrying the +6E5/Scl-lacZ/3'En construct (Tg+ mice) were obtained as described by pronuclear injection of fertilised eggs derived from (CBAxC57Bl/6)F1 x (CBAxC57Bl/6)F1 crosses. Five independent lines were generated and bred with Scl+/ heterozygous mice kindly provided by L. Robb and C. G. Begley (Robb et al., 1995) to obtain transgene positive Scl+/ mice (Tg+/Scl+/). These were intercrossed for maintenance of the transgenic lines. Embryos were derived from crosses between Tg+/Scl+/ or Tg+/+Scl+/ and Tg/Scl+/ mice.
Transgenic constructs
A unique NcoI restriction site was engineered upstream of the murine SCL open reading frame. The picornaviral internal ribosome-entry site (IRES) from the encephalomyocarditis virus (EMCV) was inserted downstream to the SCL stop codon (Mountford et al., 1994). An NcoI fragment containing the Scl-IRES-coding sequence was subcloned upstream of the lacZ gene in the +6E5/lacZ plasmid (Sanchez et al., 1999). A 5.5 kb fragment containing the 3' enhancer was then inserted downstream of the lacZ gene. The final 13 kb +6E5/Scl-lacZ/3' En insert was released by Xho/SalI digestion and introduced into fertilised eggs by pronuclear injection. To identify transgenic founders lacZ PCR analysis was performed as previously described (Sanchez et al., 1999).
Reconstitution analysis
Adult bone marrow and E11-E12 foetal liver cells were stained for FDG and FACS sorted as previously published (Sanchez et al., 1999). Sorted cells were counted, and appropriate cell number suspended in a final volume of 0.5 ml phosphate-buffered saline (PBS) for intravenous injection into the tail vein of 3- to 5-month-old irradiated females (CBAxC57Bl/6)F1 mice. Transgenic donor cells were co-injected with non transgenic 2x105 splenic cells for radioprotection. On the day of the transfer, the recipients were exposed to a split dose of total 950 RADS from an X-ray source. Mice were maintained on antibiotic water containing 0.16% neomycin sulphate (Sigma) a week before and 4 weeks after irradiation. Transplanted animals were bled from the tail vein at 1-2 months and 5-10 months post-transplantation to monitor reconstitution. Donor cell contribution was assessed semiquantitatively by PCR analysis of recipient peripheral blood DNA using lacZ and myogenin primers as previously described (Sanchez et al., 1996). Negative results were confirmed by Southern hybridisation using a lacZ probe.
Multilineage analysis of donor cell contribution
To test the contribution of donor HSCs to different haematopoietic lineages long-term transplanted mice were sacrificed at 5-12 months post-transplant. Genomic DNA was isolated from tissues or FACS-sorted cells and analysed by PCR (Sanchez et al., 1996).
Cytospin preparation and X-gal staining from the AGM region
Embryos obtained from crosses from transgenic males (line 2262) and (CBAxC57Bl/6)F1 females were removed after 11-12 days of gestation and the livers and AGM regions from individual embryos dissected out. To identify transgenic embryos, the livers were mechanically homogenised in PBS, cell suspensions stained for FDG and analysed in the flow cytometer. Cells from individual AGM regions were prepared by incubation at 37°C for 1 hour in 0.04% in collagenase (Sigma) in L-15 medium (Gibco) supplemented with 5% foetal calf serum and followed by mechanical dispersion (Sanchez et al., 1996). Cell suspensions were incubated with Fc-blocking monoclonal antibody (CD16/CD32) followed by anti CD34-biotin (RAM34) and c-Kit-PE (2B8) antibodies and then streptavidin-FITC. AGM cells from transgenic embryos were sorted, and cytospin preparations fixed for 5 minutes in 1% paraformaldehyde, 0.4% glutaraldehyde in PBS. Preparations were washed in PBS and stained overnight for X-gal. After Neutral Red counterstaining and ethanol dehydration, preparations were mounted in DPX (Sigma). All antibodies were purchased from PharMingen.
ß-galactosidase detection in whole embryos and sections
X-gal staining was performed to detect ß-galactosidase activity as previously described (Sanchez et al., 1999) with the following modifications. Founder embryos were stained for 24 hours at 37°C and embryos from established lines 48 hours at room temperature, washed in PBS and stored in fixative (1% paraformaldehyde, 0.4% glutaraldehyde in PBS). For wax sections, embryos were dehydrated in serial dilutions of ethanol, wax embedded and sectioned. For cryostat sectioning, X-gal-stained embryos were washed in PBS, incubated overnight in 25% sucrose solution, immersed in OCT embedding matrix (CellPath) and frozen on dry ice. Cryostat sections (8 µm) were counterstained with Neutral Red, dehydrated, immersed in Histoclear and mounted in EUKITT compound (Agar Scientific, UK). The embryo head was removed to obtain DNA for lacZ and Scl genotyping and the rest of the embryo was used for staining (Miles et al., 1997; Robb et al., 1995).
Fluorescence-activated cell-sorting (FACS) analysis of yolk sac cells
Individual yolk sacs were removed from E9 embryos derived from crosses between Tg+/Scl+/ or Tg+/+Scl+/ and Tg/Scl+/ mice (Tg line 2708). Cells from individual yolk sacs were prepared by incubation at 37°C for 30 minutes in 0.1% in collagenase (Sigma) in L-15 medium (Gibco) supplemented with 20% foetal calf serum and followed by mechanical dispersion (Yoder et al., 1997). The rest of the body was used for lacZ and Scl PCR genotyping. Individual cells were counted under the microscope. No cells with typical round blood morphology were detected in the Tg/Scl/ yolk sacs, instead the cells were large and vacuolated. Cells were incubated with anti-Fc receptor antibody (2.4G2) to reduce the nonspecific binding followed by incubation with the indicated antibodies and Streptavidin-PE (Pharmingen, San Diego) as the secondary reagent in PBS 5% foetal calf serum. Antibody incubations were performed at 4°C for 30 minutes. The monoclonal antibodies were from Pharmingen (San Diego, CA) and included PE-conjugated anti-Ter119, FITC-conjugated anti-c-Kit (2B8 and 3C1) and biotin-conjugated anti-CD34 (RAM34). Rat PE-conjugated IgG2a and FITC-conjugated IgG2b isotype controls were used.
In vitro colony assays for yolk sac progenitors
These were performed essentially as described (Sanchez et al., 1999). E9 embryos were derived from crosses of male Tg+/Scl+/ or Tg+/+Scl+/ with female Tg/Scl+/ mice (Tg line 2708). To avoid maternal blood contamination, anaemic embryos were separated and transferred to multiple washes in PBS 5% FCS before removal of the yolk sac. Individual yolk sacs were mechanically disaggregated by sequential passage through a 30 gauge needle in D-MEM medium (GIBCO) and the rest of the body used for lacZ and Scl PCR genotyping. Cells from each yolk sac were plated in cytokine (SCF, IL3, IL6, erythropoietin)-supplemented Methocult GF-M3434 (StemCell Technologies, Vancouver, Canada) for erythroid and myeloid colony formation. Cell suspensions from each yolk sac were split into two plates (Nunc, 4 cm plates) and the total number of colonies scored after 7 days. Erythroid colonies were assessed by staining for haemoglobin with 2,7-diaminofluorene (Sigma) (Kaiho and Mizuno, 1985). Individual colonies from two experiments were picked, genomic DNA obtained by protein kinase treatment and PCR performed for lacZ/myogenin and Scl as indicated. For cytospin preparations colonies were harvested from plates, spun onto slides and stained for May-Grunwald-Giemsa. The number of colonies analysed were as follows: a total of 28 colonies derived from three Tg+/Scl/ embryos, 20 colonies from two Tg/Scl+/+ embryos and 16 colonies from Tg+/Scl+/ embryos.
Immunohistochemistry
Whole-mount staining of embryos and yolk sacs with anti-PCAM1 monoclonal antibody (MEC13.3, Pharmingen, San Diego, CA) was performed as described previously (Schlaeger et al., 1995).
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In order to address this issue, we performed long term reconstitution experiments using irradiated adult mice as recipients. Bone marrow cell suspensions were obtained from individual adult +6E5/lacZ/3'En transgenic mice and were stained with the fluorescent ß-galactosidase substrate, FDG. As shown in Fig. 1A, two sorting regions were set according to the relative levels of lacZ expression. Varying numbers of sorted FDG+ and FDG cells were transferred intravenously into irradiated female recipient mice with 2x105 non-transgenic female splenocytes to provide short-term radioprotection (Sanchez et al., 1996). Donor cell engraftment was examined initially at 1.5-2 months and subsequently at more than 5 months post-transplantation. Recipient peripheral blood DNA was analysed by PCR for the donor lacZ transgene. Short-term engraftment was observed in animals transferred with either FDG+ or FDG cell fractions; however, long-term engraftment was detected only in recipients transplanted with FDG+ cells (Table 1). As shown for one representative experiment in Fig. 1B, as few as 103 FDG+ donor bone marrow cells produced engraftment in two out of three recipients 5 months post-transplant, while no engraftment was detected at this time point in animals transplanted with FDG cells. The cumulative results from several experiments demonstrated that lacZ transgene was readily detected by PCR more than 5 months post-transplant in almost half of recipient mice (11 out of 26) transferred with 103 to 104 FDG+ cells. By contrast, the donor lacZ transgene was not detected in any of 28 recipients transplanted with up to 106 FDG cells (Table 1). These data suggest that the vast majority of HSCs were in the FDG+ fraction. To further assess the self-renewal capacity of the FDG+ donor cells, secondary reconstitution experiments were carried out. Total bone marrow cells from a recipient mouse 5 months post-transplant were transferred into four irradiated mice (106 cells per mouse). Seven months after the second transplant, all secondary recipients exhibited high levels of reconstitution by cells carrying the lacZ transgene, thus demonstrating that cells in the original FDG+ population were capable of self-renewal (data not shown).
|
|
|
We therefore analysed whether the Scl 3' enhancer construct was capable of directing lacZ expression to HSCs present during foetal development, as well as to adult bone marrow HSCs. The embryonic AGM region is the first location during development where HSCs are detected and these cells have been shown to be c-Kit+CD34+ (Sanchez et al., 1996; Yoder et al., 1997). Previously we have shown that the 3' enhancer construct directed prominent lacZ expression to the endothelium of the dorsal aorta and to haematopoietic cells in the lumen of the vessel (Sanchez et al., 1999). In the AGM from E11 embryos, flow cytometric analysis of lacZ expression by FDG staining is not feasible. Therefore, to address whether the Scl 3'enhancer was expressed in c-Kit+CD34+ population, cell suspensions were obtained after collagenase treatment, co-stained with anti-c-Kit and anti-CD34 antibodies, and purified by FACS sorting. Cytospin preparations of c-Kit+CD34 and c-Kit+CD34+ populations were prepared and stained for lacZ expression. The majority (70%) of c-Kit+CD34+ cells expressed lacZ compared with less than 1% of the c-Kit+CD34 cells (Fig. 2). These results suggest that HSCs from the AGM region are targeted by the Scl 3' enhancer construct.
|
Multilineage reconstitution was also addressed in recipients engrafted with FDG+ foetal liver (Fig. 1F). In most recipients the level of donor cells in the peripheral blood was similar at 1-2 months and after 5 months post-transplant (Table 2). There was donor engraftment in all haematopoietic tissues analysed, except for one thymus. Within individual mice the proportion of FDG+ cells varied between individual cell lineages, with an absence of detectable donor-derived erythroid cells and macrophages in two recipients. These data demonstrate that most of the HSCs in mid-gestation foetal liver are within the FDG+ fraction and that these cells can yield multilineage repopulation.
Rescue of early haematopoiesis in Scl/ embryos by expression of SCL protein under the control of the Scl 3' enhancer
The Scl 3' enhancer provides a powerful tool for exploring HSC biology in vivo by permitting expression of exogenous genes to be targeted to the HSC compartment. Scl mutant mice die by day 9 of gestation and exhibit a complete absence of blood cell development thought to reflect a failure of HSC formation or differentiation. We reasoned that if precursors of HSCs and HSCs themselves are targeted by the Scl 3' enhancer at early developmental stages, we should be able to rescue blood development in Scl/ embryos by expression of exogenous SCL protein under control of the 3' enhancer
We therefore replaced the lacZ cDNA in the +6E5/lacZ/3'En construct with a bicistronic cassette containing the mouse Scl cDNA together with lacZ to form the +6E5/Scl-lacZ/3'En construct (Fig. 3A). After microinjection of the construct, transgene expression was assessed in midgestation founder embryos by whole-mount X-gal staining. Four transgenic embryos were analysed, three of which displayed a weak X-gal signal in the liver and vasculature detectable only after 24 hour incubation at 37°C, thus demonstrating that the +6E5/Scl-lacZ/3'En construct was functional in similar locations to the +6E5/lacZ/3'En construct (data not shown).
|
Tg+/Scl/ embryos were generated by crossing Tg+/Scl+/ or Tg+/+Scl+/ with Tg/Scl+/ mice from line 2708. The level and pattern of X-gal staining in E8 Tg+/Scl/ embryos was similar to Tg+/Scl+/embryos (Fig. 3, compare C with E). Sections of Tg+/Scl/ yolk sacs showed occasional round presumptive blood cells attached to the endothelial inner surface of blood islands and X-gal staining was observed in blood cells as well as in endothelial cells (Fig. 3F). The number of blood cells was reduced compared with the Tg+/Scl+/ control (Fig. 3, compare D with F).
E9 Tg+/Scl/ embryos were markedly anaemic and died at a time similar to Scl/ embryos (Robb et al., 1995; Shivdasani et al., 1995) (Fig. 3, compare G, J and M). However, morphological evidence of yolk sac haematopoiesis was clearly observed in yolk sac sections of E9 Tg+/ Scl/ embryos, although the number of blood cells in the blood islands was still less than in controls (Fig. 3, compare H with K and I with L). As previously reported, blood cells were not seen in yolk sacs from Tg/Scl/ embryos (Fig. 3N,O) (Robb et al., 1995; Shivdasani et al., 1995). These data demonstrate that placing exogenous Scl under control of the Scl 3' enhancer results in partial rescue of early haematopoiesis. The Scl 3'enhancer therefore directs expression to cells in which Scl exerts a non-redundant function essential for establishing early haematopoiesis.
Flow cytometry was used to characterise the haematopoietic cells in the rescued embryos (Fig. 4A; Table 3). The mean number of cells recovered per yolk sac was 161±81x103 from Tg/ Scl+/+ wild-type embryos, compared with 2.3±0.9x103 for Tg/ Scl/ embryos and to 29±15x103 from rescued Tg+/ Scl/ embryos (Table 3). Yolk sac cells were analysed for the expression of c-Kit, CD34 (both markers of haematopoietic progenitors) and Ter119 (an erythroid marker). As shown in Fig. 4A and Table 3, Tg/Scl/ yolk sacs contained very few cells positive for c-Kit, CD34 or Ter119. By contrast, rescued yolk sacs contained approximately 30-fold more cells positive for each marker. These data are consistent with the morphological evidence that rescued yolk sacs contain blood cells not seen in Scl null yolk sacs.
|
|
Colony assays were then used to assess functional haematopoietic progenitor activity in yolk sacs from rescued and wild-type embryos. Haematopoietic colonies were obtained from rescued Tg+/Scl/ embryos but not from Tg/Scl/embryos (Fig. 4B; Table 4). PCR analysis confirmed the lacZ and Scl genotype of individual colonies and excluded the possibility of contamination by Scl+/ or Scl+/+ progenitors (Fig. 4C). The number of myeloid colonies obtained from Tg+/Scl/ yolk sacs was not significantly different from the number of myeloid colonies obtained from Tg+/Scl+/ or Tg+/Scl+/+ yolk sacs. By contrast, the number of erythroid colonies from Tg+/Scl/ yolk sacs was much lower than for the other genotypes (Table 4). Cytospin preparations confirmed the presence of myeloid cells together with cells at late stages of erythroid differentiation in colonies derived from Tg+/Scl+/ yolk sacs, whereas terminally differentiated erythroblasts were not seen in colonies from rescued Tg+/Scl/ yolk sacs (Fig. 4D). We therefore conclude that expression of Scl under control of the 3' enhancer construct rescued early HSC development and permitted myeloid differentiation, but did not support full erythroid maturation. These results are consistent with our previous observation that the 3' enhancer construct is not active in Ter119-positive erythroid cells (Sanchez et al., 1999) and reveal an essential requirement for SCL during erythroid differentiation in vivo.
|
Vitelline vessels were not evident macroscopically in the yolk sacs of Tg+/Scl/ E9 embryos. However the embryos were markedly anaemic, making yolk sac vessels difficult to visualise. We therefore stained whole embryos with an antibody to PECAM, a marker of endothelial cells. The vasculature of Tg+/Scl+/ embryos appeared normal and a prominent network of vitelline vessels was evident (Fig. 5A,D). As previously reported (Visvader et al., 1998) large vitelline vessels were absent in Tg/Scl/ yolk sacs (Fig. 5B), and intraembryonic vessels appeared poorly developed (Fig. 5E). By contrast, large vitelline vessels were readily apparent in Tg+/Scl/ yolk sacs and intra-embryonic vessels also appeared normal (Fig. 5C,F). These data demonstrate that defective yolk sac and embryonic angiogenesis seen in Scl/ embryos can be rescued by expression of Scl under control of the Scl 3' enhancer. The fact that rescued embryos still die by E9-E10 presumably reflects their inability to sustain normal erythropoiesis.
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
There has been considerable interest in identifying stem cell enhancers, both to express exogenous genes in HSCs and thereby to manipulate HSC behaviour in vivo, and also to provide molecular insights into the transcriptional programme of HSCs. However, very few candidate HSC enhancers have been identified. The CD34 gene is flanked by two enhancers that are active in haematopoietic cell lines (May and Enver, 1995) but it is not known whether these elements target HSCs in vivo. A 14 kb genomic cassette containing the Ly-6E.1 gene directs lacZ expression to HSCs from adult bone marrow (Miles et al., 1997); however, the Ly-6E.1 cassette is not expressed in foetal liver or yolk sac progenitors and no individual enhancer has been shown to be sufficient to target HSCs. The H2K promotor/enhancer in combination with the Moloney MuLV enhancer will direct expression to HSCs. However, this construct is widely expressed in many cell types and the relative contribution of the H2K and retroviral enhancers to HSC expression is not clear (Domen et al., 2000).
The Scl 3' enhancer therefore provides a unique tool for manipulation of HSCs in vivo. Moreover, recent reports suggest that progenitors present in bone marrow may have a wider biological potential than previously realised, and be capable of generating hepatocytes (Lagasse et al., 2000; Petersen et al., 1999), neurones (Eglitis and Mezey, 1997) and muscle (Ferrari et al., 1998; Gussoni et al., 1999). It may therefore be possible to use the 3' enhancer to examine the molecular basis for stem cell plasticity.
Our results, together with previous data, also allow a description of the pattern of activity displayed by the Scl 3' enhancer. It is active in the region of the extra-embryonic mesoderm of E7.5 embryos that gives rise to the yolk sac, and it subsequently directs lacZ expression to endothelial and blood cells within yolk sac blood islands of E8 embryos (Sanchez et al., 1999). Within the embryo proper, the enhancer is active in endothelial cells and also in haematopoietic progenitors at diverse sites and times, including E8 para-aortic splanchnopleura, E11 AGM region and E11 foetal liver (Sanchez et al., 1999). In adult mice, the 3' enhancer is active in the vast majority of HSCs and progenitors present in bone marrow (Sanchez et al., 1999) and preliminary evidence suggests widespread expression in adult endothelial cells (L. G., unpublished).
The SCL protein is essential for the development of embryonic and adult blood in mice (Porcher et al., 1996; Robb et al., 1996), and is essential for the development of haemangioblasts from murine ES cells (Robertson et al., 2000). Furthermore ectopic expression of SCL specifies the formation of haemangioblasts from lateral mesoderm in zebrafish embryos (Gering et al., 1998), and also partially rescues the haematopoietic and endothelial defects of zebrafish cloche mutants. Taken together with these observations, the pattern of Scl 3' enhancer activity therefore suggests a model in which the 3' enhancer functions as a nodal point for the integration of signals responsible for establishing the transcriptional programme for blood and blood vessel development. Interestingly both endothelial and haematopoietic activity are retained in a 600 bp minimal enhancer fragment (B. Göttgens, unpublished). Identification of the factors that regulate this element should illuminate the molecular mechanisms controlling the origin of blood and endothelium.
Expression of Scl under control of the 3' enhancer rescues early haematopoietic progenitors and yolk sac angiogenesis in Scl/ embryos
In Scl/ mice, embryonic lethality results from a failure of HSC formation and functions together with a defect in yolk sac angiogenesis (Porcher et al., 1996; Robb et al., 1996; Visvader et al., 1998). We have demonstrated that the Scl 3' enhancer is active in adult and embryonic HSCs and is also expressed in yolk sac and embryonic endothelial cells (Sanchez et al., 1999). We therefore elected to study whether an SCL cDNA driven by the 3' enhancer would be able to rescue haematopoiesis and yolk sac angiogenesis in Scl/ embryos.
Our results show that expressing Scl under the control of the 3' enhancer rescues the formation of early haematopoietic progenitors. Normal numbers of c-Kit+ progenitors and myeloid colony-forming cells were found in the yolk sacs of rescued embryos. Interestingly, erythropoiesis remained defective with rescued yolk sacs containing markedly reduced numbers of both Ter119+ erythroid cells and erythroid colony-forming cells compared with wild-type yolk sacs. The majority of erythroid cells in E9 yolk sacs result from a wave of primitive erythropoiesis, whereas most yolk sac erythroid colony-forming cells at E9 represent definitive erythroid progenitors (Palis et al., 1999). Our data therefore suggest that both primitive and definitive erythropoiesis are deficient in rescued yolk sacs. The resultant severe anaemia is likely to be the main reason that rescued embryos still die at the same time as Scl/ embryos.
It is informative to compare our results with a previous study in which haematopoiesis in Scl/ embryos was partially rescued by Scl under the control of heterologous regulatory elements from the Gata1 gene (Visvader et al., 1998). Yolk sac angiogenesis remained abnormal, consistent with the fact that Gata1 is not expressed in the endothelial lineage, and a three- to fivefold reduction was observed in both erythroid and myeloid colony numbers, suggesting only partial rescue of the HSC compartment. By contrast, our results suggest that Scl driven by the 3' enhancer is capable of fully rescuing the stem cell compartment but is unable to support erythroid differentiation.
At least two distinct mechanisms can be envisaged. Failure to rescue normal levels of erythropoiesis could reflect an effect of abnormal levels of SCL protein in HSCs, resulting in reduced erythroid but not myeloid commitment. Indeed, relatively small alterations in the level of an individual transcription factor can have dramatic effects on lineage commitment (Heyworth et al., 1999; Kulessa et al., 1995). Alternatively the 3' enhancer construct may lack a distinct SCL erythroid enhancer which normally maintains SCL transcription during erythroid differentiation. These two mechanisms are not mutually exclusive, and rigorous discrimination between them would require fate mapping the progeny of single HSCs. However, the concept of a separate erythroid enhancer is supported by our previous observation that the 3' enhancer construct does not direct lacZ expression to cells expressing the erythroid marker Ter119 (Kina et al., 2000; Sanchez et al., 1999), whereas lacZ knocked into the Scl locus is expressed in differentiated erythroid cells (Elefanty et al., 1999). Whatever the precise mechanism, the failure to rescue erythropoiesis demonstrates a requirement for SCL during commitment to or differentiation along the erythroid lineage in vivo. A distinct role for SCL during erythroid differentiation, in addition to its role in HSC formation/function, would accord well with the previous suggestion that SCL acts as a positive regulator of erythroid differentiation in vitro (Aplan et al., 1992; Elwood et al., 1998; Valtieri et al., 1998) and with the observation that full rescue of erythropoiesis from Scl/ ES cells requires DNA binding by SCL (Porcher et al., 1999).
In addition to rescuing the generation of early haematopoietic progenitors, SCL under control of the 3' enhancer construct also rescued normal development of yolk sac vitelline vessels in Scl/ embryos. This is likely to reflect correction of a block in the ability of endothelial cells to undergo angiogenic differentiation. However, the 3' enhancer construct is probably expressed in haemangioblasts as well as in their endothelial progeny (Sanchez et al., 1999). Our data can not therefore exclude the possibility that it is endothelial commitment from haemangioblasts that is being rescued, and that the endothelial cells seen in Scl/ yolk sacs arise by a distinct developmental route (Pardanaud et al., 1996).
![]() |
ACKNOWLEDGMENTS |
---|
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Aplan, P. D., Nakahara, K., Orkin, S. H. and Kirsch, I. R. (1992). The SCL gene product: a positive regulator of erythroid differentiation. EMBO J. 11, 4073-4081.[Abstract]
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G. and Isner, J. M. (1997). Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964-967.
Begley, C. G. and Green, A. R. (1999). The SCL gene: from case report to critical hematopoietic regulator. Blood 93, 2760-2770.
Bockamp, E. O., McLaughlin, F., Murrell, A. M., Gottgens, B., Robb, L., Begley, C. G. and Green, A. R. (1995). Lineage-restricted regulation of the murine SCL/TAL-1 promoter. Blood 86, 1502-1514.
Bockamp, E. O., McLaughlin, F., Gottgens, B., Murrell, A. M., Elefanty, A. G. and Green, A. R. (1997). Distinct mechanisms direct SCL/tal-1 expression in erythroid cells and CD34 positive primitive myeloid cells. J. Biol. Chem. 272, 8781-8790.
Bockamp, E. O., Fordham, J. L., Gottgens, B., Murrell, A. M., Sanchez, M. J. and Green, A. R. (1998). Transcriptional regulation of the stem cell leukemia gene by PU.1 and Elf-1. J. Biol. Chem. 273, 29032-29042.
Ciau-Uitz, A., Walmsley, M. and Patient, R. (2000). Distinct origins of adult and embryonic blood in Xenopus. Cell 102, 787-796.[Medline]
Codias, E. K., Cray, C., Baler, R. D., Levy, R. B. and Malek, T. R. (1989). Expression of Ly-6A/E alloantigens in thymocyte and T-lymphocyte subsets: variability related to the Ly-6a and Ly-6b haplotypes. Immunogenetics 29, 98-107.[Medline]
Cross, M. A., Heyworth, C. M., Murrell, A. M., Bockamp, E. O., Dexter, T. M. and Green, A. R. (1994). Expression of lineage restricted transcription factors precedes lineage specific differentiation in a multipotent haemopoietic progenitor cell line. Oncogene 9, 3013-3016.[Medline]
Cumano, A., Dieterlen-Lievre, F. and Godin, I. (1996). Lymphoid potential, probed before circulation in mouse, is restricted to caudal intraembryonic splanchnopleura. Cell 86, 907-916.[Medline]
de Bruijn, M. F., Speck, N. A., Peeters, M. C. and Dzierzak, E. (2000). Definitive hematopoietic stem cells first develop within the major arterial regions of the mouse embryo. EMBO J. 19, 2465-2474.
Dieterlen-Lievre, F. (1975). On the origin of haemopoietic stem cells in the avian embryo: an experimental approach. J. Embryol. Exp. Morphol. 33, 607-619.[Medline]
Domen, J., Cheshier, S. H. and Weissman, I. L. (2000). The role of apoptosis in the regulation of hematopoietic stem cells: Overexpression of Bcl-2 increases both their number and repopulation potential. J. Exp. Med. 191, 253-264.
Drake, C. J. and Fleming, P. A. (2000). Vasculogenesis in the day 6.5 to 9.5 mouse embryo. Blood 95, 1671-1679.
Drake, C. J., Brandt, S. J., Trusk, T. C. and Little, C. D. (1997). TAL1/SCL is expressed in endothelial progenitor cells/angioblasts and defines a dorsal-to-ventral gradient of vasculogenesis. Dev. Biol. 192, 17-30.[Medline]
Eglitis, M. A. and Mezey, E. (1997). Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice. Proc. Natl. Acad. Sci. USA 94, 4080-4085.
Elefanty, A. G., Begley, C. G., Hartley, L., Papaevangeliou, B. and Robb, L. (1999). SCL expression in the mouse embryo detected with a targeted lacZ reporter gene demonstrates its localization to hematopoietic, vascular, and neural tissues. Blood 94, 3754-3763.
Elwood, N. J., Zogos, H., Pereira, D. S., Dick, J. E. and Begley, C. G. (1998). Enhanced megakaryocyte and erythroid development from normal human CD34(+) cells: consequence of enforced expression of SCL. Blood 91, 3756-3765.
Faloon, P., Arentson, E., Kazarov, A., Deng, C. X., Porcher, C., Orkin, S. and Choi, K. (2000). Basic fibroblast growth factor positively regulates hematopoietic development. Development 127, 1931-1941.
Ferrari, G., Cusella-De Angelis, G., Coletta, M., Paolucci, E., Stornaiuolo, A., Cossu, G. and Mavilio, F. (1998). Muscle regeneration by bone marrow-derived myogenic progenitors. Science 279, 1528-1530.
Gering, M., Rodaway, A. R., Gottgens, B., Patient, R. K. and Green, A. R. (1998). The SCL gene specifies haemangioblast development from early mesoderm. EMBO J. 17, 4029-4045.
Goodell, M. A., Brose, K., Paradis, G., Conner, A. S. and Mulligan, R. C. (1996). Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med. 183, 1797-1806.[Abstract]
Gottgens, B., McLaughlin, F., Bockamp, E. O., Fordham, J. L., Begley, C. G., Kosmopoulos, K., Elefanty, A. G. and Green, A. R. (1997). Transcription of the SCL gene in erythroid and CD34 positive primitive myeloid cells is controlled by a complex network of lineage-restricted chromatin-dependent and chromatin-independent regulatory elements. Oncogene 15, 2419-2428.[Medline]
Gottgens, B., Barton, L. M., Gilbert, J. G., Bench, A. J., Sanchez, M. J., Bahn, S., Mistry, S., Grafham, D., McMurray, A., Vaudin, M. et al. (2000). Analysis of vertebrate SCL loci identifies conserved enhancers. Nat. Biotechnol. 18, 181-186.[Medline]
Green, A. R., Salvaris, E. and Begley, C. G. (1991). Erythroid expression of the helix-loop-helix gene, SCL. Oncogene 6, 475-479.[Medline]
Green, A. R., Visvader, J., Lints, T., Harvey, R. and Begley, C. G. (1992). SCL is co-expressed with GATA-1 in haemopoietic cells but is also expressed in developing brain. Oncogene 7, 653-660.[Medline]
Gussoni, E., Soneoka, Y., Strickland, C. D., Buzney, E. A., Khan, M. K., Flint, A. F., Kunkel, L. M. and Mulligan, R. C. (1999). Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature 401, 390-394.[Medline]
Heyworth, C., Gale, K., Dexter, M., May, G. and Enver, T. (1999). A GATA-2/estrogen receptor chimera functions as a ligand-dependent negative regulator of self-renewal. Genes Dev. 13, 1847-1860.
Hwang, L. Y., Siegelman, M., Davis, L., Oppenheimer-Marks, N. and Baer, R. (1993). Expression of the TAL1 proto-oncogene in cultured endothelial cells and blood vessels of the spleen. Oncogene 8, 3043-3046.[Medline]
Ikuta, K., Kina, T., MacNeil, I., Uchida, N., Peault, B., Chien, Y. H. and Weissman, I. L. (1990). A developmental switch in thymic lymphocyte maturation potential occurs at the level of hematopoietic stem cells. Cell 62, 863-874.[Medline]
Jordan, C. T., McKearn, J. P. and Lemischka, I. R. (1990). Cellular and developmental properties of fetal hematopoietic stem cells. Cell 61, 953-963.[Medline]
Jordan, C. T., Astle, C. M., Zawadzki, J., Mackarehtschian, K., Lemischka, I. R. and Harrison, D. E. (1995). Long-term repopulating abilities of enriched fetal liver stem cells measured by competitive repopulation. Exp. Hematol. 23, 1011-1015.[Medline]
Kaiho, S. and Mizuno, K. (1985). Sensitive assay systems for detection of hemoglobin with 2,7-diaminofluorene: histochemistry and colorimetry for erythrodifferentiation. Anal. Biochem. 149, 117-120.[Medline]
Kallianpur, A. R., Jordan, J. E. and Brandt, S. J. (1994). The SCL/TAL-1 gene is expressed in progenitors of both the hematopoietic and vascular systems during embryogenesis. Blood 83, 1200-1208.
Kim, M., Cooper, D. D., Hayes, S. F. and Spangrude, G. J. (1998). Rhodamine-123 staining in hematopoietic stem cells of young mice indicates mitochondrial activation rather than dye efflux. Blood 91, 4106-4117.
Kina, T., Ikuta, K., Takayama, E., Wada, K., Majumdar, A. S., Weissman, I. L. and Katsura, Y. (2000). The monoclonal antibody TER-119 recognizes a molecule associated with glycophorin A and specifically marks the late stages of murine erythroid lineage. Br. J. Haematol. 109, 280-287.[Medline]
Kulessa, H., Frampton, J. and Graf, T. (1995). GATA-1 reprograms avian myelomonocytic cell lines into eosinophils, thromboblasts, and erythroblasts. Genes Dev. 9, 1250-1262.[Abstract]
Lagasse, E., Connors, H., Al-Dhalimy, M., Reitsma, M., Dohse, M., Osborne, L., Wang, X., Finegold, M., Weissman, I. L. and Grompe, M. (2000). Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat. Med. 6, 1229-1234.[Medline]
Lerner, C. and Harrison, D. E. (1990). 5-Fluorouracil spares hemopoietic stem cells responsible for long-term repopulation. Exp. Hematol. 18, 114-118.[Medline]
Liao, E. C., Paw, B. H., Oates, A. C., Pratt, S. J., Postlethwait, J. H. and Zon, L. I. (1998). SCL/Tal-1 transcription factor acts downstream of cloche to specify hematopoietic and vascular progenitors in zebrafish. Genes Dev. 12, 621-626.
Martin, D. I. and Whitelaw, E. (1996). The vagaries of variegating transgenes. BioEssays 18, 919-923.[Medline]
May, G. and Enver, T. (1995). Targeting gene expression to haemopoietic stem cells: a chromatin-dependent upstream element mediates cell type specific expression of the stem cell antigen CD34. EMBO J. 14, 564-574.[Abstract]
Medvinsky, A. and Dzierzak, E. (1996). Definitive hematopoiesis is autonomously initiated by the AGM region. Cell 86, 897-906.[Medline]
Miles, C., Sanchez, M. J., Sinclair, A. and Dzierzak, E. (1997). Expression of the Ly-6E.1 (Sca-1) transgene in adult hematopoietic stem cells and the developing mouse embryo. Development 124, 537-547.
Morel, F., Szilvassy, S. J., Travis, M., Chen, B. and Galy, A. (1996). Primitive hematopoietic cells in murine bone marrow express the CD34 antigen. Blood 88, 3774-3784.
Morrison, S. J., Hemmati, H. D., Wandycz, A. M. and Weissman, I. L. (1995). The purification and characterization of fetal liver hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 92, 10302-10306.[Abstract]
Mountford, P., Zevnik, B., Duwel, A., Nichols, J., Li, M., Dani, C., Robertson, M., Chambers, I. and Smith, A. (1994). Dicistronic targeting constructs: reporters and modifiers of mammalian gene expression. Proc. Natl. Acad. Sci. USA 91, 4303-4307.[Abstract]
Mucenski, M. L., McLain, K., Kier, A. B., Swerdlow, S. H., Schreiner, C. M., Miller, T. A., Pietryga, D. W., Scott, W. J., Jr. and Potter, S. S. (1991). A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis. Cell 65, 677-689.[Medline]
Muller, A. M., Medvinsky, A., Strouboulis, J., Grosveld, F. and Dzierzak, E. (1994). Development of hematopoietic stem cell activity in the mouse embryo. Immunity 1, 291-301.[Medline]
Muller-Sieburg, C. E., Whitlock, C. A. and Weissman, I. L. (1986). Isolation of two early B lymphocyte progenitors from mouse marrow: a committed pre-pre-B cell and a clonogenic Thy-1-lo hematopoietic stem cell. Cell 44, 653-662.[Medline]
Okada, S., Nakauchi, H., Nagayoshi, K., Nishikawa, S., Miura, Y. and Suda, T. (1991). Enrichment and characterization of murine hematopoietic stem cells that express c-kit molecule. Blood 78, 1706-1712.[Abstract]
Osawa, M., Hanada, K., Hamada, H. and Nakauchi, H. (1996). Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science 273, 242-245.[Abstract]
Palis, J., Robertson, S., Kennedy, M., Wall, C. and Keller, G. (1999). Development of erythroid and myeloid progenitors in the yolk sac and embryo proper of the mouse. Development 126, 5073-5084.
Pardanaud, L., Luton, D., Prigent, M., Bourcheix, L. M., Catala, M. and Dieterlen-Lievre, F. (1996). Two distinct endothelial lineages in ontogeny, one of them related to hemopoiesis. Development 122, 1363-1971.
Petersen, B. E., Bowen, W. C., Patrene, K. D., Mars, W. M., Sullivan, A. K., Murase, N., Boggs, S. S., Greenberger, J. S. and Goff, J. P. (1999). Bone marrow as a potential source of hepatic oval cells. Science 284, 1168-1170.
Porcher, C., Swat, W., Rockwell, K., Fujiwara, Y., Alt, F. W. and Orkin, S. H. (1996). The T cell leukemia oncoprotein SCL/tal-1 is essential for development of all hematopoietic lineages. Cell 86, 47-57.[Medline]
Porcher, C., Liao, E. C., Fujiwara, Y., Zon, L. I. and Orkin, S. H. (1999). Specification of hematopoietic and vascular development by the bHLH transcription factor SCL without direct DNA binding. Development 126, 4603-4615.
Rebel, V. I., Miller, C. L., Thornbury, G. R., Dragowska, W. H., Eaves, C. J. and Lansdorp, P. M. (1996). A comparison of long-term repopulating hematopoietic stem cells in etal liver and adult bone marrow from the mouse. Exp. Hematol. 24, 638-648.[Medline]
Robb, L., Lyons, I., Li, R., Hartley, L., Kontgen, F., Harvey, R. P., Metcalf, D. and Begley, C. G. (1995). Absence of yolk sac hematopoiesis from mice with a targeted disruption of the scl gene. Proc. Natl. Acad. Sci. USA 92, 7075-7079.[Abstract]
Robb, L., Elwood, N. J., Elefanty, A. G., Kontgen, F., Li, R., Barnett, L. D. and Begley, C. G. (1996). The scl gene product is required for the generation of all hematopoietic lineages in the adult mouse. EMBO J. 15, 4123-4129.[Abstract]
Robertson, S. M., Kennedy, M., Shannon, J. M. and Keller, G. (2000). A transitional stage in the commitment of mesoderm to hematopoiesis requiring the transcription factor SCL/tal-1. Development 127, 2447-2459.
Sanchez, M. J., Holmes, A., Miles, C. and Dzierzak, E. (1996). Characterization of the first definitive hematopoietic stem cells in the AGM and liver of the mouse embryo. Immunity 5, 513-525.[Medline]
Sanchez, M., Gottgens, B., Sinclair, A. M., Stanley, M., Begley, C. G., Hunter, S. and Green, A. R. (1999). An SCL 3' enhancer targets developing endothelium together with embryonic and adult haematopoietic progenitors. Development 126, 3891-3904.
Schlaeger, T. M., Qin, Y., Fujiwara, Y., Magram, J. and Sato, T. N. (1995). Vascular endothelial cell lineage-specific promoter in transgenic mice. Development 121, 1089-1098.
Shivdasani, R. A., Mayer, E. L. and Orkin, S. H. (1995). Absence of blood formation in mice lacking the T-cell leukaemia oncoprotein tal-1/SCL. Nature 373, 432-434.[Medline]
Silver, L. and Palis, J. (1997). Initiation of murine embryonic erythropoiesis: a spatial analysis. Blood 89, 1154-1164.
Sinclair, A. M., Gottgens, B., Barton, L. M., Stanley, M. L., Pardanaud, L., Klaine, M., Gering, M., Bahn, S., Sanchez, M., Bench, A. J. et al. (1999). Distinct 5' SCL enhancers direct transcription to developing brain, spinal cord, and endothelium: neural expression is mediated by GATA factor binding sites. Dev. Biol. 209, 128-142.[Medline]
Spangrude, G. J., Heimfeld, S. and Weissman, I. L. (1988). Purification and characterization of mouse hematopoietic stem cells. Science 241, 58-62.[Medline]
Trevisan, M. and Iscove, N. N. (1995). Phenotypic analysis of murine long-term hemopoietic reconstituting cells quantitated competitively in vivo and comparison with more advanced colony-forming progeny. J. Exp. Med. 181, 93-103.[Abstract]
Tsai, F. Y., Keller, G., Kuo, F. C., Weiss, M., Chen, J., Rosenblatt, M., Alt, F. W. and Orkin, S. H. (1994). An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature 371, 221-226.[Medline]
Uchida, N. and Weissman, I. L. (1992). Searching for hematopoietic stem cells: evidence that Thy-1.1lo Lin- Sca-1+ cells are the only stem cells in C 7BL/Ka-Thy-1.1 bone marrow. J. Exp. Med. 175, 175-184.[Abstract]
Valtieri, M., Tocci, A., Gabbianelli, M., Luchetti, L., Masella, B., Vitelli, L., Botta, R., Testa, U., Condorelli, G. L. and Peschle, C. (1998). Enforced TAL-1 expression stimulates primitive, erythroid and megakaryocytic progenitors but blocks the granulopoietic differentiation program. Cancer Res. 58, 562-569.[Abstract]
Visser, J. W., Bauman, J. G., Mulder, A. H., Eliason, J. F. and de Leeuw, A. M. (1984). Isolation of murine pluripotent hemopoietic stem cells. J. Exp. Med. 159, 1576-1590.[Abstract]
Visvader, J., Begley, C. G. and Adams, J. M. (1991). Differential expression of the LYL, SCL and E2A helix-loop-helix genes within the hemopoietic system. Oncogene 6, 187-194.[Medline]
Visvader, J. E., Fujiwara, Y. and Orkin, S. H. (1998). Unsuspected role for the T-cell leukemia protein SCL/tal-1 in vascular development. Genes Dev. 12, 473-479.
Wang, L. C., Swat, W., Fujiwara, Y., Davidson, L., Visvader, J., Kuo, F., Alt, F. W., Gilliland, D. G., Golub, T. R. and Orkin, S. H. (1998). The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow. Genes Dev. 12, 2392-2402.
Wang, Q., Stacy, T., Binder, M., Marin-Padilla, M., Sharpe, A. H. and Speck, N. A. (1996). Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc. Natl. Acad. Sci. USA 93, 3444-3449.
Weissman, I., Papaioannou, V. and Gardner, R. (1978). Fetal hematopoietic origins of the adult hematolymphoid system. In Differentiation of Normal and Neoplastic Hematopoietic Cells (ed. B. Clarkson et al.), pp. 33-47. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
Yoder, M. C., Hiatt, K., Dutt, P., Mukherjee, P., Bodine, D. M. and Orlic, D. (1997). Characterization of definitive lymphohematopoietic stem cells in the day 9 murine yolk sac. Immunity 7, 335-344.[Medline]